阿托伐他汀对糖耐量减低原发性高血压患者血管内皮功能的影响

摘要

目的 探讨阿托伐他汀对糖耐量减低的原发性高血压(EH)患者血管内皮功能的影响.方法 EH合并糖耐量减低患者96例,随机分为对照组(常规治疗,50例),阿托伐他汀组(常规治疗+阿托伐他汀20 mg/d,46例).观察治疗前和治疗8周后血脂、血糖及血压变化,采用流式细胞术检测治疗前后外周血CD31+/AnnexinV+内皮微粒(EMPs)数量.结果 治疗后,阿托伐他汀组外周血EMPs数量明显减少[(2342.5±856.2)个/ml vs.(1806.7±761.7)个/ml](P＜0.01),对照组无明显变化[(2251.8±832.5)个/ml vs.(2152.5±815.1)个/ml](P＞0.05).治疗后,阿托伐他汀组甘油三酯(TG)、总胆固醇(TC)及低密度脂蛋白(LDL)水平明显低于对照组(P＜0.05).结论 阿托伐他汀能显著降低EH合并糖耐量减低患者外周血EMPs数量,减轻内皮凋亡和损伤.%Objective To investigate the effects of atorvastatin on vascular endothelial function in the patients with essential hypertensive (EH) and impaired glucose tolerance. Methods A total of 96 EH patients with impaired glucose tolerance was divided into two groups of A(50 cases, with conventional therapy) and B(46 cases, treated with additional atorvastatin 20 mg/d for 2 weeks). Plasma CD31+/Annexin V+ endothelial microparticles (EMPs) were measured by flow cytometry before and 8 weeks after treatment. The changes of blood lipids, glucose and BP were recorded as well. Results Plasma EMPs in group B were significantly lower after treatment than those before [(2342. 5±856. 2) pieces/ml vs. (1806. 7 + 761. 7) pieces/ml](P<0. 01) , which were not in group A [(2251. 8±832. 5) pieces/ml vs. (2152. 5 + 815. 1) pieces/ml](P>0. 05). Plasma levels of TG,TC and LDL after treatment were lower in group B than those in group A(P<0. 05). Conclusion Atorvastatin can decrease plasma EMPs, reduce the injury and apoptosis of endothelium in EH patients with impaired glucose tolerance.